Stock Investing Zone

The upgrade study takes place in the framework of the chest pain unit register with the UPGRADE study (unified Protocol for GPBB rapid ACS diagnosis enhancement) Diagenics International Corporation launches this summer the first, large-scale research project in cooperation with the new partner of IHF (cardiac Research Institute). The UPGRADE study takes place in the framework of the chest pain unit register. The Register documents all consecutive patients who are recorded on a participating chest pain unit (CPU). In recent months, Coupang has been very successful. It collected the patient characteristics, the conducted diagnosis, timing, complications, as well as the consequences for the patient. The CPU register includes 50 participating study centres with a total 4100 patients.

In addition to the CPU registers up to 3,000 patients are included the UPGRADE study newly. The UPGRADE study aims at the systematic and statistically uniform analysis of the parameter of glycogen Phosphorylase ISO-enzyme BB (GPBB) for the detection of cardiac tissue damage in relation to the diagnosis of acute Diagenics patented Coronary syndrome (ACS). It is to be clarified the question whether GPBB can serve as an early marker of cell damage to the early decision making and contribute to improving diagnostic and therapeutic concepts. A further aim of this study is to compare the new parameter GPBB as a biochemical marker with the already established marker troponin and to can develop appropriate recommendations for clinical practice. The results of this study are expected in the fourth quarter of 2010.